Press Releases

SutroVax Announces Closing of $64M via Series B Financing

Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of a $60 million Series B financing. The financing was led by new investors…

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma

SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling studies, including preparation for GLP toxicology, of STRO-001, an antibody drug conjugate, or ADC, that targets CD74, a protein highly expressed in B-cell malignancies.  STRO-001 demonstrated efficient cell…

Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma

SAN FRANCISCO, Sept. 19, 2016 — Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it developed to target CD74, a protein highly expressed in hematologic malignancies.  The ADCs demonstrated efficient cell killing in multiple malignant…

Sutro Appoints Shabbir T. Anik Chief Technical Operations Officer

SOUTH SAN FRANCISCO, June 1, 2016 – Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical operations officer. Dr. Anik brings over 30 years of experience in pharmaceutical technology, drug development, manufacturing operations and strategic alliance-building…

Sutro Expands Senior Leadership Team with Addition of Chief Medical Officer and VP of Translational Pharmacology and Preclinical Development

SOUTH SAN FRANCISCO, Mar. 9, 2016 – Sutro Biopharma today announced the appointment of Arturo Molina, M.D., M.S., FACP as chief medical officer and Mark Lupher, Ph.D., as vice president of translational pharmacology and preclinical development (TP&PD). Both Dr. Molina and Dr. Lupher bring exceptional…

Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association

SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ — Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association (CLSA) annual Pantheon Ceremony 2015 Presenting DiNA Awards.  Late last year, Sutro entered into a broad strategic collaboration and option agreement with Celgene…